Akebia Therapeutics, Par settle Auryxia suit

Akebia Therapeutics’ subsidiary, Keryx Biopharmaceuticals and its licensor Panion & BF Biotech have entered into a settlement and license agreement with Par Pharmaceutical, an Endo International, resolving patent litigation brought by Keryx and Panion in response to Par’s abbreviated new drug application to market a generic version of Auryxia (ferric citrate) tablets prior to the expiration of the applicable patents.

The companies will grant Par a license to market its generic version of Auryxia in the United States beginning on March 20, 2025 (subject to FDA approval), or earlier under certain circumstances customary for settlement agreements of this nature.

Additionally, in accordance with the agreement, the parties will terminate all ongoing Hatch-Waxman litigation between Keryx and Panion and Par regarding Auryxia patents pending in the U.S. District Court for the District of Delaware and the U.S. District Court for the Southern District of New York.

“We are pleased to have reached this settlement and believe it reinforces the strength of our intellectual property, including the fifteen patents listed in the Orange-Book that cover Auryxia,” Akebia president and CEO John Butler said.

The agreement is confidential and subject to review by the Federal Trade Commission and the Department of Justice.